Bristol-Myers signs deal with U.N. group for generic hepatitis C drug A United Nations-backed organization working to cut the price of HIV drugs said it had signed a deal with Bristol-Myers Squibb Co to allow generic versions of the company's hepatitis C drug to be sold in 112 low- and middle-income countries.The drug, Daklinza, is on the World Health Organization's list of essential medicines.Hepatitis C affects about 150 million people globally and kills around half a million each year, the World Health Organisation estimates.The Medicines Patent Pool said on Monday that Daklinza would now be available to nearly two-thirds of people affected by the disease in low- and middle-income countries. The list price in the United States for Daklinza is $63,000 for a 12-week regimen, or about $750 per day at wholesale costs, according to pharmacy benefits manager Express Scripts.Other drugs used to treat hepatitis C include Gilead Sciences' Sovaldi. A single Sovaldi pill costs $1,000 in the United States, according to Express Scripts. The deal with Bristol-Myers allows drugmakers anywhere in the world to develop generic versions of Daklinza. The Medicines Patent Pool had earlier signed a deal with Bristol-Myers for generic versions of its HIV treatment Reyataz. (Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr)
France vows 'merciless' response after attacks kill 127
Dallas police chief expresses worry about armed civilians in Texas
Chipotle shuts Seattle, Portland stores after E. coli outbreak